Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
